Our Collaborators
We work with leading researchers to investigate the benefits of Mitoquinol Mesylate across health and disease.
Prof. Mike Murphy
Mitochondrial biology, redox chemistry
Co-inventor of mitoquinol, Prof. Murphy is a global leader in mitochondrial-targeted therapeutics. His foundational work focuses on targeting antioxidants to mitochondria to reduce oxidative stress and improve cellular function.
University: University of Cambridge
Prof. Doug Seals
Vascular ageing, cardiovascular physiology
Leads clinical research investigating mitoquinol to improve endothelial function and reduce arterial stiffness in older adults by targeting mitochondrial ROS.
University of Colorado Boulder
Assistant Research Professor, University of Colorado.Dr Matthew Rossman
Endothelial function, vascular ageing
Focuses on the mechanistic effects of mitoquinol on nitric oxide bioavailability and mitochondrial oxidative stress in ageing vasculature.
Trial: Age-related vascular dysfunction (NCT04851288)
Professor, Medicine-Geriatrics. University of Colorado, Boulder.Prof. Kerrie Moreau
Women’s cardiovascular health, ageing
Researches sex-specific vascular ageing and the role of mitochondrial oxidative stress, with a focus on improving endothelial function in women.
Assistant Professor. University of Colorado Denver - Anschutz Medical CampusDr Zachary Clayton
Vascular physiology, oncology, environmental and clinical physiology
Dr Clayton is investigating the concurrent administration of mitoquinol alongside chemotherapy (e.g., doxorubicin), with a focus on mitigating treatment-induced oxidative stress and vascular dysfunction—an emerging application of mitochondrial-targeted antioxidants in oncology supportive care.
Medical College of WisconsinDr Matthew Durand
Vascular health, stroke recovery
Leads clinical research evaluating mitoquinol to improve vascular function and functional outcomes in stroke survivors.
Assistant Professor. University of Colorado Denver - Anschutz Medical CampusDr Vienna Brunt
Medicine-Renal Med Diseases/Hypertension
Dr Brunt is involved in research investigating mitoquinol in autosomal dominant polycystic kidney disease (ADPKD), where mitochondrial dysfunction and oxidative stress are believed to contribute to disease progression.
This work explores whether targeting mitochondrial ROS can provide a novel therapeutic approach for renal and vascular complications associated with ADPKD.
Medical College of WisconsinDr Jennifer McIntosh
Pregnancy complications, placental vascular function
Leads clinical research investigating mitoquinol as a therapeutic for preeclampsia, with a focus on restoring placental blood flow and improving maternal–fetal outcomes.
Her work is further supported by major external funding, including a grant from the Gates Foundation global challenges, recognising the global health potential of targeting mitochondrial dysfunction in pregnancy-related disease.